Morphoproteomic and pharmacoproteomic correlates in hormone-receptor- negative breast carcinoma cell lines

Annals of Clinical and Laboratory Science

Volumn 34, Issue 3, 2004, Pages 251-262

  Brown, Robert E ^a   Lun, Mingyue ^b   Prichard, Jeffrey W ^a   Blasick, Thomas M ^b   Zhangl, Ping L ^a,b  

^a GEISINGER MEDICAL CENTER   (United States)

^b WEIS CENTER FOR RESEARCH   (United States)

Author keywords

Breast carcinoma; Cancer chemotherapy; Immunohistochemistry; Proteomics; Western blotting

Indexed keywords

ALPHA INTERFERON; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HORMONE RECEPTOR; IMATINIB; LIGAND; PLATELET DERIVED GROWTH FACTOR; PROTEIN; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; RECEPTOR;

ARTICLE; BREAST CARCINOMA; BRIGHT FIELD MICROSCOPY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL COMPARTMENTALIZATION; CELL PROLIFERATION; CELL STRAIN MDA 175; CELL STRAIN MDA 231; CELL STRAIN SKBR 3; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG EFFECT; HUMAN; HUMAN CELL; IMAGING SYSTEM; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SCORING SYSTEM; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CAPTOPRIL; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HORMONES; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON-ALPHA; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; PIPERAZINES; PROTEOMICS; PYRIMIDINES; RECEPTORS, CELL SURFACE;

ACIS;

EID: 4444247627     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Murray PA, Gomm J, Ricketts D, Powles T, Coombes RC. The effect of endocrine therapy on the levels of oestrogen and progesterone receptor and transforming growth factor-beta 1 in metastatic human breast cancer: an immunocytochemical study. Eur J Cancer 1994;30A:1218-1222.
2. Brown RE, Bernath AM, Lewis GO. HER-2/neu protein-receptor-positive breast carcinoma: an immunologic perspective. Ann Clin Lab Sci 2000;30:249-258.
3. Thor A. HER2 - a discussion of testing approaches in the USA. Ann Oncol 2001;12(Suppl 1):S101-107.
4. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003;8:303-306.
5. Cohen MH, Dagher R, Griebel DJ, Ibrahim A, Martin A, Scher NS, Sokol GH, Williams GA, Pazdur R. U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid. Oncologist 2002;7:393-400.
6. Ross DM, Hughes TP. Cancer treatment with kinase inhibitors: what have we learnt from imatinib? Br J Cancer 2004;90:12-19.
7. Brower V. Of cancer and cholesterol: studies elucidate anticancer mechanisms of statins. J Natl Cancer Inst 2003;95:844-846.
8. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998;13:581-589.
9. Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000;373:231-241.
10. Lipton A. Bisphosphonates and metastatic breast carcinoma. Cancer 2003;97:848-853.
11. Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000;15:2211-2221.
12. DiBianco R. Angiotensin converting enzyme inhibition. Unique and effective therapy for hypertension and congestive heart failure. Postgrad Med 1985;78:229-241.
13. Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD, Molteni A, Polverini PJ, Bouck NP. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 1996;98:671-679.
14. Fleming T, Borer J, Armstrong PW, Pfeffer M. Food and Drug Administration. Cardiovascular and Renal Drugs Advisory Committee. Food and Drug Administration: Cardiovascular and Renal Drugs Advisory Committee, 98th Meeting, January 6-7, 2003. Circulation 2003;107:e9002-9003.
15. Rivera E, Arrieta O, Guevara P, Duarte-Rojo A, Sotelo J. AT1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma. Br J Cancer 2001;85:1396-1399.
16. Moriguchi Y, Matsubara H, Mori Y, Murasawa S, Masaki H, Maruyama K, Tsutsumi Y, Shibasaki Y, Tanaka Y, Nakajima T, Oda K, Iwasaka T. Angiotensin II-induced transactivation of epidermal growth factor receptor regulates fibronectin and transforming growth factor-beta synthesis via transcriptional and posttranscriptional mechanisms. Circ Res 1999;84:1073-1084.
17. Miller JL. Sirolimus approved with renal transplant indication. Am J Health Syst Pharm 1999;56:2177-2178.
18. Hosoi H, Dilling MB, Shikata T, Liu LN, Shu L, Ashmun RA, Germain GS, Abraham RT, Houghton PJ. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 1999;59:886-894.
19. Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 2003;3:371-377.
20. Grunt ThW, Dittrich E, Offterdinger M, Schneider SM, Dittrich Ch, Huber H. Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells. Br J Cancer 1998;78:79-87.
21. Herbert BS, Sanders BG, Kline K. N-(4-hydroxyphenyl)-retinamide activation of transforming growth factor-beta and induction of apoptosis in human breast cancer cells. Nutr Cancer 1999;34:121-132.
22. Roberson KM, Penland SN, Padilla GM, Selvan RS, Kim CS, Fine RL, Robertson CN. Fenretinide: induction of apoptosis and endogenous transforming growth factor beta in PC-3 prostate cancer cells. Cell Growth Differ 1997;8:101-111.
23. Jinno H, Steiner MG, Mehta RG, Osborne MP, Telang NT. Inhibition of aberrant proliferation and induction of apoptosis in HER-2/neu oncogene transformed human mammary epithelial cells by N-(4-hydroxyphenyl) retinamide. Carcinogenesis 1999;20:229-236.
24. Twombly R. First proteasome inhibitor approved for multiple myeloma. J Natl Cancer Inst 2003;95:845.
25. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ. The proteasome as a target for cancer therapy. Clin Cancer Res 2003;9:6316-6325.
26. Brown RE. HER-2/neu-positive breast carcinoma: molecular concomitants by proteomic analysis and their therapeutic implications. Ann Clin Lab Sci 2002;32:12-21.
27. Brown RE. Histogenesis of Reed-Sternberg and dendritic interdigitating cells in nodular sclerosing Hodgkin's disease. Immunohistochemical evidence for monocytoid precursors. Ann Clin Lab Sci 1997;27:329-337.
28. Sun W, Zhang PL, Herrera GA. p53 protein and Ki-67 overexpression in urothelial dysplasia of bladder. Appl Immunohistochem Mol Morphol 2002;10:327-331.
29. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-145.
30. McGary EC, Weber K, Mills L, Doucet M, Lewis V, Lev DC, Fidler IJ, Bar-Eli M. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res 2002;8:3584-3591.
31. Small W Jr, Molteni A, Kim YT, Taylor JM, Chen Z, Ward WF. Captopril modulates hormone receptor concentration and inhibits proliferation of human mammary ductal carcinoma cells in culture. Breast Cancer Res Treat 1997;44:217-224.
32. Small W Jr, Molteni A, Kim YT, Taylor JM, Ts'ao CH, Ward WF. Mechanism of captopril toxicity to a human mammary ductal carcinoma cell line in the presence of copper. Breast Cancer Res Treat 1999;55:223-229.
33. Wong J, Rauhoft C, Dilley RJ, Agrotis A, Jennings GL, Bobik A. Angiotensin-converting enzyme inhibition abolishes medial smooth muscle PDGF-AB biosynthesis and attenuates cell proliferation in injured carotid arteries: relationships to neointima formation. Circulation 1997;96:1631-1640.
34. Rosewicz S, Weder M, Kaiser A, Riecken EO. Antiproliferative effects of interferon alpha on human pancreatic carcinoma cell lines are associated with differential regulation of protein kinase C isoenzymes. Gut 1996;39:255-261.
35. Tiefenbrun N, Kimchi A. The involvement of protein kinase C in mediating growth suppressive signals of interferons in hematopoietic cells. Oncogene 1991;6:1001-1007.
36. Powell CB, Manning K, Collins JL. Interferon-alpha (IFN-alpha) induces a cytolytic mechanism in ovarian carcinoma cells through a protein kinase C-dependent pathway. Gynecol Oncol 1993;50:208-214.
37. Brown RE. Interferon-alpha therapy, protein kinase C-alpha and Langerhans cell histiocytosis. Med Pediatr Oncol 2003;41:63-64.
38. Lindemann RK, Braig M, Ballschmieter P, Guise TA, Nordheim A, Dittmer J. Protein kinase Calpha regulates Ets1 transcriptional activity in invasive breast cancer cells. Int J Oncol. 2003;22:799-805.
39. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidyinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 2002;62:4132-4141.
40. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD 1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001;61:8887-8895.
41. Normanno N, Campiglio M, De LA, Somenzi G, Maiello M, Ciardiello F, Gianni L, Salomon DS, Menard S. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 2002;13:65-72.
42. Anderson NG, Ahmad T, Chan K, Dobson R, Bundred NJ. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int J Cancer 2001;94:774-782.
43. Takahashi T, Taniguchi T, Konishi H, Kikkawa U, Ishikawa Y, Yokoyama M. Activation of Akt/protein kinase B after stimulation with angiotensin II in vascular smooth muscle cells. Am J Physiol 1999;276:H1927-1934.
44. Chen EY, Mazure NM, Cooper JA, Giaccia AJ. Hypoxia activates a platelet-derived growth factor receptor/phosphatidylinositol 3-kinase/Akt pathway that results in glycogen synthase kinase-3 inactivation. Cancer Res 2001;61:2429-2433.
45. Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA, Giese NA. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 2002;62:3729-3735.
46. Park CS, Schneider IC, Haugh JM. Kinetic analysis of platelet-derived growth factor receptor/phosphoinositide 3-kinase/Akt signaling in fibroblasts. J Biol Chem 2003;278:37064-37072.
47. Frasca F, Vigneri P, Vella V, Vigneri R, Wang JY. Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to hepatocyte growth factor. Oncogene 2001;20:3845-3856.
48. Kohlstedt K, Brandes RP, Muller-Esterl W, Busse R, Fleming I. Angiotensin-converting enzyme is involved in outside-in signaling in endothelial cells. Circ Res 2004;94:60-67.
49. Ryan MJ, Sigmund CD. ACE, ACE inhibitors, and other JNK. Circ Res 2004;94:1-3.
50. Costanzo A, Moretti F, Burgio VL, Bravi C, Guido F, Levrero M, Puri PL. Endothelial activation by angiotensin II through NF-kappaB and p38 pathways: Involvement of NF-kappaB-inducible kinase (NIK), free oxygen radicals, and selective inhibition by aspirin. J Cell Physiol 2003;195:402-410.
51. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999;401:82-85.
52. Burow ME, Weldon CB, Melnik LI, Duong BN, Collins-Burow BM, Beckman BS, McLachlan JA. PI3-K/AKT regulation of NF-kappaB signaling events in suppression of TNF-induced apoptosis. Biochem Biophys Res Commun 2000;271:342-345.
53. Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT, Pergamenschikov A, Williams CF, Zhu SX, Lee JCF, Lashkari D, Shalon D, Brown PO, Botstein D. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 1999;96:9212-9217.